| Title | The cholesteryl ester transfer protein taql B polymorphism is associated with improved response to atorvastatin therapy in Greek patients | |
| Authors | Antonis Goulas¹, Maria S. Kosmidou², Apostolos I. Hatzitolios², Dimitra Molyva¹, Liana Fidani³, Georgios Parharidis⁴ and Vasiliki Mirtsou¹
1. Department of Exp. Pharmacology 2. 1st Propedeutic Department of Internal Medicine 3. Department of General Biology 4. 1st Department of Cardiology, School of Medicine, Aristotle Univesity, Thessaloniki 54124, Greece |
|
| Citation | Goulas, A., Kosmidou, M.S., Hatzitolios, A.I., Molyva, D., Fidani, L. et al: The cholesteryl ester transfer protein taql B polymorphism is associated with improved response to atorvastatin therapy in Greek patients, Epitheorese Klin. Farmakol. Farmakokinet. 20(2): 94-96 (2006) | |
| Publication Date | Accepted for publication: 19-20 May 2006 | |
| Full Text Language | English | |
| Order – Buy | Ηλεκτρονική Μορφή: pdf (10 €) – Digital Type: pdf (10 €)
pharmakonpress[at]pharmakonpress[.]gr |
|
| Keywords | Cholesteryl ester transfer protein, lipoproteins, HDL-C, atorvastatin, pharmacogenetics. | |
| Other Terms | review article | |
| Summary | Cholesteryl ester transfer protein (CETP) plays a vital role in lipid homeostasis, by facilitating the transfer of cholesteryl esters from high density lipoprotein (HDL) to triglyceride rich lipoproteins. A number of studies have addressed the issue of a possible association be- tween polymorphisms in the CETP gene and the efficacy of statin treatment, but the results have been inconclusive. ln our study we examined the effect of the CETP Taql 8 polymorphism on the plasma lipid concentration changes induced by a daily dose of 10 mg of atorvastatin in 40 prospectively enrolled Greek dyslipidemic patients. Plasma lipid and lipoprotein levels were measured before and after a 4-week follow-up. CETP Taql 8 genotypes were scored with a restriction fragment length polymorphism (RFLP) protocol. After adjustment for covariates, CETP 8282 homozygotes showed a greater HDL cholesterol (HDL-C) increase compared to 8182 and 8181 genotypes (16,9% vs. 3,2% and -1,5%, P = 0,002). No statistically significant association was observed with respect to other lipid parameters. Our results are in favor of the CETP Taql 8 polymorphism exerting an influence on the response to atorvastatin and indicate that dyslipidemic patients with the 8282 genotype may benefit more in terms of HDL-C improvement, compared to 81 carriers. | |
| References | 1. Genest J.J., McNamara J.R., Salem B.N., Schaefer E.J.: Prevalence of risk factors in man with premature coronary artery disease. Am. J. Cardiol. 67: 1185-1189 (1991)
2. Tall A.R.: Plasma cholesteryl ester transfer protein. J. Lipid Res. 34: 1255-1274 (1993) 3. Foger B., Ritsch A., Doblinger A., Wessels A., Patsch J.R.: Relationship of plasma cholesteryl ester transfer protein to HDL cholesterol. Studies in normotriglyceridemia and moder hypertriglyceridemia. Arterioscler. Thromb. Vasc. Biol. 16: 1430-1436 (1996) 4. Doggrell S.A.: lnhibitors of cholesteryl ester transfer protein – a step forward in the treatment of coronary artery disease?: Drugs Fut. 30: 45-50 (2005) 5. Ordovas J.M., Cupples L.A., Corella D., et al.: Association of cholesteryl ester transfer protein-TaqlB polymorphism with variations in lipoprotein sub-classes and coronary heart risk: The Framingham study. Arterioscler. Thromb. Vasc. Biol. 20: 1323-1329 (2000) 6. Boekholdt S.M., Thompson J.F.: Natural genetic variation as a tool in understanding the role of CETP in lipid concentrations and in disease. J. Lipid Res. 44: 1080-1093 (2003) 7. Kajinami K., Takekoshi N., Brousseau M.E., Schaefer E.J.: Pharmacogenetics of HMG-CoA reductase inhibitors: exploring the potential for genotype-based individualization of coronary heart disease management. Atherosclerosis 177: 219- 234 (2004) 8. Cuchel M., Wolfe M.L., de Lemos A.S., Rader D.J.: The frequency of the cholesteryl ester transfer protein Taq1 B2 allele is lower in African Americans than in Caucasians. Atherosclerosis 163: 169-174 (2002) 9. Winkelman B.R., Hoffmann M.M., Nauck M., et al.: Haplotypes of the cholesteryl ester transfer protein predict lipid-modifying response to statin therapy. Pharmacogenomics J. 3: 284-296 (2003) 10. van Venrooij F.V., Stolk R.P., Banka J.D., et al.: Common cholesteryl ester transfer protein gene polymorphisms and the effect of atorvastatin therapy in type 2 diabetes. Diabetes Care 26: 1216-1223 (2003) 11. Boekholdt S.M., Sacks F.M., Jukema J., et al.: Cholesteryl Ester Transfer Protein TaqlB Variant, high-density lipoprotein cholesterol levels, cardiovascular risk, and efficacy of parvastatin treatment. Individual Patient Meta-Analysis of 13677 subjects. Circulation 111: 278-287 (2005) 12. de Grooth G.J., Zerba K.E., Huang S.P., et al.: The cholesteryl ester transfer protein (CETP) TaqlB polymorphism in the cholesterol and recurrent events study: no interaction with response to pravastatin therapy and no effects on cardiovascular outcome. J. Am. Coll. Cardiol. 43: 854-857 (2004) 13. Fiegenbaum M., Silveira F.R., van der Sand C., et al.: Pharmacogenetic study of apolipoprotein E, cholesteryl ester transfer protein and hepatic lipase genes and simvastatin therapy in Brazilian subjects. Clin. Chim. Acta 362: 182-188 (2005) |
|
| Relative Papers |
Online ISSN 1011-6575
Άρθρα Δημοσιευμένα σε αυτό το Περιοδικό Καταχωρούνται στα:
- Chemical Abstracts
- Elsevier’s Bibliographic Databases: Scopus, EMBASE, EMBiology, Elsevier BIOBASE SCImago Journal and Country Rank Factor
Articles published in this Journal are Indexed or Abstracted in: • Chemical Abstracts • Elsevier’s Bibliographic Databases: Scopus, EMBASE, EMBiology, Elsevier BIOBASE SCImago Journal and Country Rank Factor
Συντακτικη Επιτροπή-Editorial Board
| ΕΤΗΣΙΑ ΣΥΝΔΡΟΜΗ 2006 – ANNUAL SUBSCRIPTION 2006 | |
| Γλώσσα Πλήρους Κειμένου – Full Text Language | Αγγλικά – English |
| Παραγγελία – Αγορά – Order – Buy | Ηλεκτρονική Μορφή: pdf (70 €) – Digital Type: pdf (70 €)
pharmakonpress[at]pharmakonpress[.]gr |
| Έντυπη Μορφή (70 € + έξοδα αποστολής) – Printed Type (70 € + shipping)
pharmakonpress[at]pharmakonpress[.]gr |
|